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The level of response (LR) to alcohol as measured with the Self‐Report of the Effects
of Alcohol Retrospective Questionnaire (SRE) evaluates the number of standard
drinks usually required for up to four effects. The need for a higher number of drinks
for effects is genetically influenced and predicts higher risks for heavy drinking and
alcohol problems. We conducted genome‐wide association study (GWAS) in the
African‐American (COGA‐AA, N = 1527 from 309 families) and European‐American
(COGA‐EA, N = 4723 from 956 families) subsamples of the Collaborative Studies
on the Genetics of Alcoholism (COGA) for two SRE scores: SRE‐T (average of first
five times of drinking, the period of heaviest drinking, and the most recent 3 months
of consumption) and SRE‐5 (the first five times of drinking). We then meta‐analyzed
the two COGA subsamples (COGA‐AA + EA). Both SRE‐T and SRE‐5 were modestly
heritable (h2: 21%‐31%) and genetically correlated with alcohol dependence (AD) and
DSM‐IV AD criterion count (rg: 0.35‐0.76). Genome‐wide significant associations© 2019 Society for the Study of Addictionwileyonlinelibrary.com/journal/adb 1 of 11
2 of 11 LAI ET AL.were observed (SRE‐T: chromosomes 6, rs140154945, COGA‐EA P = 3.30E‐08 and
11, rs10647170, COGA‐AA+EA P = 3.53E‐09; SRE‐5: chromosome13, rs4770359,
COGA‐AA P = 2.92E‐08). Chromosome 11 was replicated in an EA dataset from
the National Institute on Alcohol Abuse and Alcoholism intramural program. In silico
functional analyses and RNA expression analyses suggest that the chromosome 6
locus is an eQTL for KIF25. Polygenic risk scores derived using the COGA SRE‐T
and SRE‐5 GWAS predicted 0.47% to 2.48% of variances in AD and DSM‐IV AD
criterion count in independent datasets. This study highlights the genetic contribution
of alcohol response phenotypes to the etiology of alcohol use disorders.
KEYWORDS
genetic correlation, genome‐wide association study (GWAS), heritability, polygenic risk score, RNA
expression, self‐rating of the effects of ethanol (SRE)1 | INTRODUCTION
A low level of response (LR) to alcohol, a measure of the intensity of
reaction to alcohol as evaluated by either alcohol challenges, or a
self‐report questionnaire regarding the number of standard drinks
needed for a range of effects is an important predictor of the future
development of alcohol dependence (AD).1 AD is associated with
considerable morbidity and affects about 12.5% of the US population
during their lifetime.2 Typically, individuals who experience fewer
intoxicating or sedating effects of alcohol are more likely to escalate
their drinking behaviors.3 Thus, low LR has been related to future
problems with alcohol primarily via heavy consumption,3 even after
accounting for histories of heavy drinking4 and family history.5 Multi-
ple putative pathways, including overly positive expectations of the
effects of alcohol, heavier peer drinking, and using alcohol to cope
with stress,3 have also been found to contribute to the heightened risk
for AD in those with low LR. Interestingly, recent research suggests
college‐based prevention programs that target LR are effective in
individuals with low, but not high, LR.6,7 Thus, even though low LR is
a marker for predisposition to AD, largely via heavy consumption,
individual differences in LR are also associated with unique sources
of variance.
A person's LR can be measured by administering an alcohol chal-
lenge, either through oral ingestion or intravenously, and recording
the individual's level of reaction over several hours. Such alcohol‐
administration paradigms are time‐consuming and costly, making it
difficult to evaluate large numbers of subjects.1 LR can also bemeasured
by the retrospective Self‐Report of the Effects (SRE) of Alcohol Ques-
tionnaire, in which participants estimate the number of standard drinks
usually required to experience up to four different effects of alcohol
(feel an effect; feel dizzy or slurring speech; stumble or walk in an unco-
ordinated manner; pass out or fall sleep) at three time periods (first five
times of drinking, the period of heaviest drinking, and the most recent
3 months of consumption). SRE scores and LRmeasured during an alco-
hol challenge are correlated (r = 0.3‐0.6), suggesting that the easier to
collect SRE can be used in large‐scale studies to measure LR.1,8,9 SREscores also have an 1 year test‐retest correlation between 0.72 and
0.82 and 5‐year retest of 0.66, indicating high levels of reliability.8,9
Their predictive validities regarding future heavy drinking and alcohol
problems across different populations and sexes in studies conducted
in the United States, United Kingdom, and Switzerland are also consis-
tent.4,10-15 These studies cumulatively indicate that an individual's LR,
as measured by the SRE, could serve as an additional risk marker for
the development of problem drinking, and can be a useful tool in efforts
to personalize prevention and treatment.6
Both AD and LR (self‐report or alcohol challenge results) are
heritable.11,16,17 While there have been numerous efforts to identify
genetic variants for AD,18 there have been only a few studies
examining the genetic contributions to SRE. Two linkage studies, one
using 745 European ancestry individuals (included in this study)19
and another in American Indians,20 detected modest evidence of link-
age. Recently, a meta‐analysis of genome‐wide association studies
(GWAS) of SRE score of the first five times of drinking (SRE‐5) did
not identify genome‐wide significant loci.21 Genetic analyses of the
average SRE scores across the three time periods (SRE‐T) have been
limited to candidate gene studies.22 A recent analysis showed that
polygenic risk scores derived from a GWAS of alcohol consumption
in a large UK population of older adults explained minimal variance
in SRE‐T23 suggesting that even at a polygenic level, SRE scores might
be associated with unique genetic variation. Given the importance of
SRE as a predictor of problem drinking, and its role in intervention
research, the identification of such variants is necessary.
We conducted genome‐wide association studies of SRE scores in
the Collaborative Study on the Genetics of Alcoholism (COGA). First,
using variance decomposition approaches for family data, we
estimated the heritability of the SRE scores in the African‐American
and European‐American COGA subsamples. The covariance between
SRE‐T, SRE‐5, AD (defined by DSM‐IV), and DSM‐IV AD criterion
count (used as a measurement of severity of AD) was decomposed
into its genetic and environmental sources. We then performed
GWAS to identify genetic variants contributing to the variation in
SRE‐T and SRE‐5 scores. Genome‐wide significant loci were examined
LAI ET AL. 3 of 11in two independent datasets and in RNA expression analysis using
brain tissue from individuals with AD and controls. Finally, we derived
polygenic risk scores (PRS) from these discovery GWAS and evaluated
whether the polygenic effects of SRE‐related variants predicted AD
and DSM‐IV AD criterion count in four independent AA and EA
datasets.2 | METHODS
2.1 | Sample and assessments
AD probands from alcohol use disorder inpatient and outpatient
treatment facilities and their family members were recruited from
the seven participating COGA sites. Comparison individuals and their
families were ascertained from the community in the same seven
areas.24 Institutional review boards at all sites approved the study
and all participants provided informed consent.
The SRE of Alcohol Questionnaire9 is a self‐report instrument used
to measure the number of standard drinks required to produce up to
four effects of alcohol at three different time periods: (a) the first five
times the subject used alcohol; (b) the period of heaviest drinking; and
(c) the most recent 3 months of consumption. For each time period,
the subject is asked: (a) “How many (standard) drinks did it take for
you to begin to feel an effect?”; (b) “How many drinks did it take for
you to feel a bit dizzy or begin to slur your speech?”; (c) “How many
drinks did it take you to begin to stumble or walk in an uncoordinated
manner?”; (d) “Howmany drinks did it take you to pass out or fall asleep
when you did not want to?” Extreme observations were winsorized at
the mean plus two standard deviations and only individuals who drank
at least two drinks on one occasion were included in the analysis. On
the basis of their distributions, the square root of SRE‐T and the natural
logarithm of SRE‐5 were used in analyses. Distributions of original and
transformed SRE scores are in supplemental material.
The Semi‐Structured Assessment for the Genetics of Alcoholism
(SSAGA) interview and an adolescent version of the SSAGA24 were
administered to adults and individuals age 17 or under, respectively.
An AD case was defined as an individual age 15 or older who met
the DSM‐IV criteria for AD, to exclude early onset AD, which may
have different etiology.25 Control subjects were at least 21 years old
and had consumed at least one full drink of alcohol in their lifetime,
but who did not endorse more than one DSM‐IV AD criterion. We
set the minimum age as 21 to exclude individuals who had not have
passed through the period of major risk for the onset of AD.26,27 All
others were not classified. Although these unclassified individuals
were not used in any analysis related to DSM‐IV AD, they were
included in all other analysis (eg, GWAS of SRE scores).2.2 | Genotyping, quality review, and imputation
COGA samples were generated on four arrays: Illumina Human1M
array (Illumina, San Diego, CA, USA) genotyped at the Center for
Inherited Disease Research (CIDR), Johns Hopkins University; IlluminaHuman OmniExpress 12 V1 array (Illumina, San Diego, CA, USA)
genotyped at the Genome Technology Access Center, Washington
University School of Medicine in St. Louis; Illumina 2.5M array
(Illumina, San Diego, CA, USA) at CIDR; and Smokescreen genotyping
array (Biorealm LLC, Walnut, CA, USA) genotyped at Rutgers Univer-
sity. Two to 127 samples were genotyped on at least two different
arrays and pairwise concordance rates within subjects typed on more
than one array exceeded 99.18% for those common SNPs, confirming
limited batch or array effects. Sex and heterogeneity checks were
performed and any discrepancies were removed.
To confirm pedigree structure, a set of 47 000 variants genotyped
on all four arrays were used. These variants met the following criteria:
(a) not in linkage disequilibrium (LD, defined as r2 < .5); (b) minor allele
frequency (MAF) greater than 10%; (c) Hardy‐Weinberg equilibrium
(HWE) P value > 0.001; and (d) missing rate less than 2%. Pairwise
identity by descent was computed using PLINK28 to confirm family
relationships. When necessary, family structures were altered
accordingly. The same set of 47 000 variants were also used to esti-
mate principal components (PCs) of population stratification using
Eigenstrat.29 On the basis of the first two PCs, each individual was
assigned an ancestry (ie, African‐American, European‐American, or
other). Family ancestry was assigned on the basis of the individual
ancestry of the greatest proportion of family members.
Prior to imputation, Mendelian inconsistences were detected using
Pedcheck,30 and genotype inconsistences were set to missing. Vari-
ants with missing rates > 5%, MAF < 3%, and HWE P values < 0.0001
were excluded. In addition, variants with A/T or C/G alleles were also
removed to avoid ambiguities in strand designation. SHAPEIT2,31
which utilizes pedigree information to increase accuracy, was used
to phase haplotypes of each sample. All samples were imputed to
1000 genomes the cosmopolitan reference panel (Phase 3, version 5,
http://www.internationalgenome.org/) using Minimac3.32 Because of
the differences in the variants on each array, samples were imputed
separately by array. After imputation, variants with R2 < 0.30 were
excluded. To allow for further Mendelian error checking, genotype
probabilities were converted to genotypes if they were greater than
0.90 (similar to procedures for QC and analysis of family data in
Walters et al18; see also Kranzler et al that used converted
genotypes33). All genotype and imputed variants with missing rates
less than 20%, MAF ≥ 1%, and HWE P values > 0.000001 were used
in analyses. Variants that passed QC were 15 464 468 and 7 823 558
and were included in the AA and EA subsamples analyses, respec-
tively. All variants were mapped to NCBI GRCh37.2.3 | Heritability, genetic correlations, and GWAS
All analyses were performed separately in COGA AA (COGA‐AA) and
EA (COGA‐EA) subsamples, then meta‐analyzed (COGA‐AA + EA).
Because of the complex pedigree structure in COGA, methods using
genome‐wide genotype data such as Genome‐wide complex traits
analysis34 could not be used to estimate heritability or genetic correla-
tions. Instead, using an approach similar to those applied in classical twin
4 of 11 LAI ET AL.studies, the Sequential Oligogenic Linkage Analysis Routines
(SOLAR8.3.1)35 package, which was designed to partition variance in
large pedigrees, was used to estimate heritability of SRE scores (ie, pro-
portion of total phenotypic variance attributable to latent genetic influ-
ences), as well as the genetic correlations between the SRE measures
and AD and DSM‐IV AD criterion count.35 Sex and birth cohorts (birth
year: 1890‐1929; 1930‐1949; 1950‐1969; ≥1970) were important
covariates as shown in previous studies36; therefore both of them and
the first four PCs were used as covariates in SOLAR analyses.
GWAS was conducted using linear mixed models with random
effects adjusting for relatedness within families using the R package
GWAF.37 Sex, birth cohorts, array indicators, and the first four PCswere
included as covariates. METAL38 was used to perform meta‐analysis
with effect size of each variantweighted by the inverse of the estimated
standard error from each subsample. Genomic control was applied to
the results of each subsample as well as to the meta‐analysis results.
As SRE‐T and SRE‐5 were highly correlated (correlation coefficients
were 0.75 and 0.78 in COGA‐AA and COGA‐EA, respectively), we used
matSpD39 to spectrally decompose the correlationmatrix of SRE scores,
resulting 1.44 effective test. Thus, the genome‐wide significance was
set at P < 3.5 × 10−8. In regions of genome‐wide significance, conditional
analyseswere performed by including themost significant variant in the
region as a covariate.2.4 | Gene prioritization
FUMA,40 a web‐based tool that incorporates information frommultiple
public databases, was used to prioritize potentially causal genes. Three
gene prioritization strategies are implemented in FUMA: positional
mapping, expression Quantitative Trait Locus (eQTL) mapping, and
chromatin interaction mapping. Positional mapping annotates variants
based on their physical positions and functional consequences. For
any region in which at least one variant met genome‐wide significance,
all variants in that region with P values≤ 1.0E‐04 were annotated. If an
annotated variantwas in the promoter or untranslated regions (UTRs) of
a gene, or in exonic or splicing regions of a gene and predicted to be del-
eterious, that gene was prioritized as a potential causal gene. Ensembl
(build 85; http://www.ensembl.org/)was used tomap variants to genes.
For eQTL mapping, genes within 1 Mb of the most significant variant
were tested, and those with significant associations (defined as
FDR < 0.05) were considered as potential causal genes. eQTL data from
brain tissues in BRAINEAC (http://www.braineac.org/), CommonMind
Consortium (https://www.synapse.org), and GTEx v7 (https://www.
gtexportal.org/) were used. Genes prioritized by any of these three
strategies were considered as potential causal genes and further
examined by subsequent RNA expression analysis.2.5 | RNA expression analysis
To test the associations between the most significant variants and
gene expressions, human autopsy brain samples were obtained from
the New South Wales Brain Tissue Resource Centre (NSWBTRC) atthe University of Sydney (http://sydney.edu.au/medicine/pathology/
btrc/). Fresh frozen samples of the superior frontal cortex
(Brodmann area 8) were used. This region was selected because a
prior enrichment analysis suggests aggregation of AD‐associated
GWAS signals in this brain region.41 In addition, there was an ade-
quate sample size available for this region. The samples were
sequenced on Illumina Hi‐Seq (Illumina, CA, USA) at the New York
Sequencing center (N = 83) and at the Waggoner Center for Alcohol
and Addiction Research (N = 60). Total RNA was extracted from
frozen tissue and samples with contamination or degraded quality
RNA (RNA integrity numbers [RIN] < 5.0) were excluded. Samples of
138 passed quality review and were used in the analysis (65 AD and
73 age‐ and sex‐matched controls). The KAPA Stranded RNA‐Seq
Kit with RiboErase was used for library preparation. The library QC
included a measurement of the average size of library fragments using
the Fragment Analyzer (Advanced Analytical Technologies, IA, USA),
and estimation of the total concentration of DNA by PicoGreen
(Thermo Fisher Scientific, MA, USA). Raw reads were aligned to
human genome 19 (hg19) using STAR aligner.42 Quality control was
assessed using RSeQC43 and Picard (% GC, % duplicates, gene
body coverage, unsupervised clustering, and library complexity,
http://broadinstitute.github.io/picard/). The Picard “MarkDuplicates”
option was used to flag and remove the duplicate reads. Gene quanti-
fication was performed with featureCounts using Gencode annota-
tions. We filtered out all genes with lower expression in a
substantial fraction of the cohort, with 18 463 genes with at least
1 CPM (counts per million) in at least 50% of the individuals; note that
only these genes were carried forward in all subsequent analyses.
DNA was extracted from the same brain tissue samples used in the
RNA analysis. Genotyping was performed on the Axiom Biobank Plus
Genotyping Array (Catalog number: 000854). Initial QC was
performed using PLINK28 to remove variants with: (a) no alternate
alleles; (b) genotyping call rate ≤ 0.98; (c) Hardy‐Weinberg Equilibrium
P value < 5E‐5; and (d) samples with genotyping call rate < 0.90.
Phasing was performed on each chromosome using SHAPEIT2,31 then
imputation was done using IMPUTE244 with the 1000 Genomes
Phase 1 integrated reference panel excluding singleton variants.
Analysis was performed on the imputed variants with imputation
score (INFO) ≥ 0.8 and estimated MAF ≥ 0.05.
eQTLs were computed using a linear model on the imputed geno-
type dosages using Matrix EQTL69.45 If the most significant variant
was filtered out in this sample because of QC, the next available
variant with the lowest P value and in LD (r2 > .9) with the most
significant variant was tested instead. The gene expression data were
adjusted for sex, age, post‐mortem interval, RIN, batch, and decedent
phenotype (AD or control).2.6 | Replication samples
The first replication dataset was from the San Diego Sibling Pair inves-
tigation and genotyped on the Illumina HumanCNV370‐duo array
(Illumina, San Diego, CA, USA). This study was approved by the
LAI ET AL. 5 of 11Human Subjects Protection Committee of the University of California,
San Diego. The same quality review and imputation used in COGA
were performed. This dataset included both unrelated and related
individuals. Empirical kinships were estimated from genome‐wide
genotype data using the vcf2kinship tool as implemented in RVTESTS
and adjusted in mixed models using RVTESTS.46 The majority of the
dataset had European ancestry; therefore, only EA samples was used
(SD‐EA, N = 206, 68 AD cases and 138 controls). Only sex was avail-
able and included as a covariate.
Two datasets from the National Institute on Alcohol Abuse and
Alcoholism (NIAAA) Intramural program were also used as replication.
Participants were recruited under two NIH Institutional Review
Board‐approved screening and assessment protocols andwere compre-
hensively assessed at the National Institutes of Health Clinical Center
(Bethesda, Maryland, USA) between 2005 and 2015. All participants
provided written informed consent. Genotyping was conducted at the
NIAAA Laboratory of Neurogenetics (Rockville, MD, USA) using the
Illumina Human OmniExpress and Human OmniExpressExome arrays.
The same quality review and imputation as in COGA were performed;
169 (130 AD cases, 27 controls, and 12 not classified) and 100 (36 AD
cases, 27 controls, and 12 not classified) unrelated AA (NIAAA‐AA)
and EA (NIAAA‐EA) individuals were used in analyses, respectively.
Sex and age were included as covariates. Only AA samples were
adjusted for the first three PCs because unlike COGA‐EA, EA samples
in replication and PRS analysis did not include non EA individuals.
2.7 | Polygenic risk scores analyses
Summary statistics from both SRE scores in COGA‐AA and COGA‐EA
were used to derive PRS using PRSice‐2.47 Four test datasets from the
database of genotypes and phenotypes (dbGaP) were included: (a) AA
subsample (SAGE‐AA) in the Study of Addiction: Genetics and Environ-
ment (SAGE, phs000092.v1.p1); (b) AA subsample (Yale‐Penn‐AA) in
Alcohol Dependence GWAS in European and African Americans
(phs000425.v1.p1); (c) EA subsample in SAGE (SAGE‐EA); and (d) EA
subsample (OZALC‐EA) in The Australian Twin‐family Study of Alcohol
Use Disorder (OZALC, phs000181.v1.p1). Overlapping COGA
individuals were excluded from these independent datasets. PRSice‐
2 requires the analysis of unrelated samples; therefore, in datasets
with related individuals, one individual was randomly selected from
each family. Summary of each test dataset is shown in supplementalTABLE 1 Summary of COGA‐AA and COGA‐EA subsamples
Sample
number of
family
number of
individual % AD
number of AD
casea (%male)
number of AD
controlb (%mal
COGA‐AA 309 1527 32.74 500 (58.60) 421 (28.50)
COGA‐EA 956 4723 36.35 1717 (60.51) 1336 (27.77)
Total 1265 6250
Abbreviations: AD, alcohol dependence; AA, African‐American; COGA, Collabo
aIndividuals who met the DSM‐IV criteria for AD but younger than 15 were no
bIndividuals who had two DSM‐IV criteria, never drank, or younger than 21 wematerial. Any variant that was within 500 kb from the index variant
and had r2 ≥ 0.25, with the index variant was clumped using
PRSice‐2. PRS was calculated on the basis of effect size.47 To reduce
the burden of multiple testing, only variants that had P values < 0.05
were included. For SAGE, sex and the same birth cohort as defined
in COGA were included as covariates, while for Yale‐Penn‐AA and
OZALC‐EA, sex and age were used. The first three PCs were also
adjusted in AA samples.3 | RESULTS
3.1 | Sample summary, heritability, and genetic
correlations
Table 1 summarizes the COGA‐AA and COGA‐EA subsamples. Com-
pared with those in COGA‐AA, individuals in COGA‐EA had higher
mean DSM‐IV AD criterion count in both AD cases and controls,
SRE‐T, and SRE‐5 scores. Latent genetic influences (familial h2) con-
tributed to 21% to 31% of the variance in SRE scores, indicating mod-
erate heritability (Table 2). Overall, genetic correlations (rg) with AD
and DSM‐IV AD criterion count were higher for SRE‐T (rg = 0.49‐
0.76) than for SRE‐5 (rg = 0.35‐0.48) (Table 2).3.2 | GWAS results
Two loci for SRE‐T (chromosome 6 for COGA‐EA; chromosome 11 for
COGA‐AA + EA) and one locus for SRE‐5 (chromosome 13 for COGA‐
AA) reached genome‐wide significance (Table 3, Figure S2). Tables S1
and S2 provide a broader list of association results (P < 1E‐04) for
SRE‐T and SRE‐5, respectively.
SRE‐T: the most significant association results were with variants on
chromosome 11 in COGA‐AA + EA (most significant: rs10647170,
P = 3.53E‐09), with both subsamples providing supporting evidence
for the association. Evaluation of rs10647170 in independent datasets
provided nominal evidence of replication in the NIAAA‐AA (P = 0.05),
but not in the SD‐EA or NIAAA‐EA (Table 3) samples. Meta‐analysis
of COGA‐EA + AA and the three replication datasets resulted in a lower
P value of 6.45E‐10.
In addition, a genome‐wide significant result was noted with
a variant on chromosome 6 (rs140154945, P = 3.30E‐08) ine)
Mean AD DSM‐IV
criterion count
(stdev) in cases
Mean AD DSM‐IV
criterion count
(stdev) in controls
Mean SRE‐T
(stdev)
Mean SRE‐5
(stdev)
5.05 (1.46) 0.19 (0.39) 4.55 (2.86) 3.36 (2.08)
5.14 (1.54) 0.21 (0.41) 5.26 (2.78) 3.73 (1.98)
rative Studies on the Genetics of Alcoholism; EA, European American.
t classified.
re not classified.
TABLE 2 Heritability, genetic correlations between AD, DSM‐IV AD criterion count and SRE scores
AD DSM‐IV AD criterion count
Sample Phenotype Heritability (P value) Genetic correlation P value Genetic correlation P value
COGA‐AA SRE‐T 0.21 (4.10E‐06) 0.76 1.25E‐07 0.63 4.20E‐06
COGA‐AA SRE‐5 0.20 (6.35E‐05) 0.48 1.88E‐03 0.40 6.13E‐03
COGA‐EA SRE‐T 0.31 (1.14E‐35) 0.61 4.55E‐25 0.49 8.26E‐19
COGA‐EA SRE‐5 0.31 (7.01E‐34) 0.41 4.52E‐11 0.35 9.44E‐10
Abbreviations: AD, alcohol dependence; AA, African‐American; COGA, Collaborative Studies on the Genetics of Alcoholism; EA, European American.
6 of 11 LAI ET AL.COGA‐EA (Table 3) that not supported in COGA‐AA. There was also
no evidence of replication for rs140154945 in the EA replication
datasets.
Regional association plots demonstrated strong LD support in both
the chromosomes 6 and 11 regions (Figures S3A, S3B, and S3C).
Conditional analyses using the top variant in each region as a covariate
confirmed that there were no additional association signals in these
chromosomal regions associated with SRE‐T.
SRE‐5: genome‐wide significant associations were identified in
COGA‐AA on chromosome 13 (rs4770359, P = 2.92E‐08), although
it was not associated in COGA‐EA (Table 3). The variant was not
replicated in the NIAAA‐AA. There was modest LD support in this
region possibly because of unusual LD pattern as shown in 1000
genomes data using LDlink (https://ldlink.nci.nih.gov/?tab=home)
(Figures S3D and S4). Unlike SRE‐T, conditional analyses found that
some variants demonstrated modest association (P < 0.001) after
adjustment of the top variant, suggesting that additional independent
associations might exist in each region, consistent with the LD
patterns showing in Figure S3D. There were no genome‐wide signifi-
cant association findings in COGA‐AA + EA and COGA‐EA GWAS.
The effect sizes of the most significant variants in each locus
in discovery and replication samples are shown in the forest plots in
Figure S5.3.3 | Gene prioritization and RNA expression
analysis
For chromosome 11, one variant (rs2270678, COGA‐AA + EA
P = 1.81E‐08) was located in the 5′ UTR of PRMT3 (protein arginine
methyltransferase 3). Another variant (rs3781679, COGA‐AA + EA
P = 3.58E‐05, Table S1) was located in the 3′ UTR of HTATIP2 (HIV‐
1 Tat interactive protein 2). Therefore, both genes were prioritized
in FUMA. Chromatin interaction mapping further prioritized DBX1
(developing brain homebox 1) and SLC6A5 (solute carrier family 6
member 5) in this region. On chromosome 6, three variants were
located in the 3′ UTR of AFDN (adherens junction formation factor)
(Table S1) and this gene was therefore prioritized by FUMA. eQTL
analysis further prioritized the gene KIF25 (kinesin family member
25) in this region (multiple variants had FDR < 0.01). No genes were
prioritized in the chromosome 13 region.For the six genes prioritized by FUMA (Chromosome 11: PRMT3,
HTATIP2, DBX1, SLC6A5; Chromosome 6: AFDN, KIF25), RNA expres-
sion in brain tissue obtained from NSWBRTC was examined. After
adjusting for six tests, the Bonferroni correction threshold was set at
P < 0.0083. Rs140154945 did not pass QC in this smaller postmortem
tissue sample, therefore, the next most significant variant in high LD
(rs3778662, COGA‐EA P = 7.24E‐08, r2 = 0.92 with rs140154945)
was used. After adjustment for covariates, including AD status of
decedent, rs3778662 was identified as an eQTL of KIF25
(P = 6.62E‐05).3.4 | PRS analyses
PRS analysis results are summarized in Table 4. For both SRE‐T and
SRE‐5, there are four discovery‐test dataset pairs (i.e., Bonferroni
P < 0.0125). Overall, PRS from SRE‐T outperformed those from SRE‐
5 in prediction of AD phenotypes; PRS of both SRE‐T and SRE‐5 pre-
dicted greater variance in DSM‐IV AD criterion count than AD;
prediction was also higher in EA than in AA samples. The strongest
finding was for polygenic scores based on the COGA‐EA SRE‐T
GWAS, which predicted 2.48% of the variance in AD in the SAGE‐EA.4 | DISCUSSION
This is the first GWAS to identify common variants associated with
SRE‐T and the first GWAS of SRE scores in AA samples. This is also
the first study to report genome‐wide significant findings for any
SRE score. These findings are not under linkage regions previously
published19,20 using SRE‐5. Of the genome‐wide significant loci,
the locus on chromosome 11 was nominally replicated in one
sample, although the replication sample was small. Of the genes pri-
oritized for SRE‐T in the EA sample, KIF25 was supported by data
from both in silico functional analyses and RNA expression analysis.
In addition, PRS derived from these discovery GWAS of SRE
predicted variance in AD‐related phenotypes in independent
datasets. Broadly, these GWAS analyses suggest that larger samples
of SRE phenotypes, particularly SRE‐T, might be highly informative
in the identification of loci related to LR, which influences risk for
development of AD and is emerging as a notable target for
prevention.
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TABLE 4 Results of PRS derived using COGA SRE GWAS summary statistics. P < 0.0125 are in bold
AD DSM‐IV AD Criterion Count
Discovery dataset Test dataset R2 P value R2 P value
SRE‐T COGA‐EA SAGE‐EA 2.48% 4.13E‐07 1.37% 8.55E‐07
SRE‐T COGA‐EA OZALC‐EA 0.34% 0.05 0.60% 1.14E‐03
SRE‐T COGA‐AA SAGE‐AA 1.49% 6.10E‐03 1.04% 1.72E‐03
SRE‐T COGA‐AA Yale‐Penn‐AA 0.36% 0.03 0.05% 0.33
SRE‐5 COGA‐EA SAGE‐EA 0.88% 2.37E‐03 0.61% 1.08E‐03
SRE‐5 COGA‐EA OZALC‐EA 0.14% 0.21 0.47% 3.85E‐03
SRE‐5 COGA‐AA SAGE‐AA 0.53% 0.10 0.34% 0.07
SRE‐5 COGA‐AA Yale‐Penn‐AA 0.0007% 0.92 0.03% 0.43
8 of 11 LAI ET AL.SRE‐T and SRE‐5 represent self‐reported assessments of LR. SRE‐
T and SRE‐5 were moderately heritable, but our estimates were lower
than some prior reports. For instance, a smaller (n = 101) sibling study
of nonalcohol‐dependent individuals estimated the heritability of SRE‐
T at 67% to 71%,11 although the corresponding estimate for an “early
drinking period” was lower and statistically nonsignificant. Similar high
heritability estimates have been noted for other assessments of
subjective ratings (eg, 40%‐60%).16,48 It is possible that our estimates
are less precise than those from larger twin studies, as we relied on
pedigree data. We did not utilize genomic data to estimate the SNP‐
heritability of SRE scores as our large pedigrees, when reduced to a
smaller cohort of unrelated individuals, is not well‐powered to make
such estimates. Nonetheless, our estimates suggest that future larger
efforts should be successful in estimating the extent to which
common variants explicate the heritability of SRE.49
Our discovery GWAS in both COGA‐AA and COGA‐EA identified
genome‐wide significant loci. The association signal on chromosome
11 was supported by both COGA‐AA and COGA‐EA. Genes priori-
tized in this region have been supported by other GWAS. In a recent
GWAS of alcohol dependence in a Thai population, the region
between DBX1 and PRMT3 showed suggestive association with
AD.50 Another study reported an association between PRMT3 and
smoking.51 Variants upstream of PRMT3 demonstrated suggestive
association with marijuana‐dependence criterion count in an African‐
American cohort.52 Although HTAPIP2 in this region was also
prioritized by FUMA, it was not reported to be related to any neuro-
psychiatric diseases. Two additional genes in this region, DBX1 and
SLC6A5, were prioritized by chromatin interaction mapping. DBX1
has been linked to educational achievement,53 which is negatively
correlated with genetic liability to alcohol dependence,18 while
SLC6A5 was reported to be related to schizophrenia,54 which is posi-
tively genetically correlated with AD.18 Thus, there is increasing
evidence for the involvement of variants in this region to liability to
problem drinking.
Analyses of RNA expression data in brain tissue identified KIF25
on chromosome 6 to be a gene of interest for SRE‐T in the EA sample.
The minor alleles of the associated variants in this region increased the
SRE‐T score, risk of AD, and expression of KIF25 in both curated braintissue data (eg, from GTEx) and RNA expression analysis that
accounted for AD status. Because of the small sample size, there
was insufficient statistical power to analyze the effects of variants
stratified by cases and controls. This gene encodes a protein that
belongs to the kinesin‐like protein family. A region that is approxi-
mately 40 kb away from KIF25 was shown to be associated with
Attention Deficit Hyperactivity Disorder.55 However, there are few
functional studies of this gene and its exact role in alcohol‐related
behaviors remains unknown. Nonetheless, these results highlight the
importance of KIF25 expression in LR.
Individuals with low LR, and consequently, higher SRE scores are at
increased likelihood of drinking heavily and developing problems AD.1
The present study found that a preponderance of this correlation is
attributable to genetic factors, as indexed by strong correlations in
latent heritable factors influencing SRE and AD phenotypes. However,
these high correlations should be interpreted within the context of our
ascertainment strategy, which oversampled for individuals with family
history of AD. It should also be distinguished from more recent SNP‐
based genetic correlations that examine the extent of similarity
between genome‐wide effect sizes for two traits. In contrast to the
high rg from the pedigree data, our study also added a novel explora-
tion of the extent to which polygenic liability to SRE relates to AD.
Overall, PRS mostly explained modest proportions of variance in AD
phenotypes. Nearly 2.5% and 1.4% of the variance in AD diagnosis
and criterion count, respectively, were explained by polygenic liability
to SRE‐T in the SAGE‐EA data. Predictions were less significant in
other target cohorts, potentially because of the similar ascertainment
for alcohol dependence of SAGE and COGA. For example, even
though Yale‐Penn‐AA was ascertained for alcohol dependence, it has
a high rate of other illicit drug dependence which may have impacted
predictions. Polygenic liability to SRE‐5 was poorly related to AD phe-
notypes, consistent with its lower genetic correlation with AD diagno-
sis and criterion count.
Our results suggest that some polygenic liability underlying SRE‐T
and AD is common but also highlight that each phenotype is likely to
be influenced by unique genetic factors. For instance, the current
strongest signal for AD, rs1229984 in ADH1B,18 was not associated
at genome‐wide significant levels to SRE‐T (EA P = 0.00027; AA
LAI ET AL. 9 of 11P = 0.019; rs2066702, strongest signal in AA, P = 0.012). Similarly, the
most significant variant for SRE‐T in chromosome 11, rs10647170,
was not associated with AD (P > 0.18 in COGA‐AA, COGA‐EA, and
COGA‐AA‐EA). Thus, the genetic variants associated with SRE and
those relating to AD are likely to only modestly overlap. For example,
the AD risk is associated with high impulsivity and sensation seeking,
low conscientiousness, and the risk for some psychiatric disorders
(eg, schizophrenia), characteristics that have little, if any, links to LR.
This study has several limitations. Despite the size of the COGA
discovery samples, power to detect association with low frequency
variants is modest. Likewise, sample sizes of the replication datasets
were small, raising the possibility that true findings were not replicated.
Despite this, one association was confirmed by theNIAAA samples, and
meta‐analyses of all datasets resulted in increased significance of
genome‐wide significant signals. Additionally, we used hard‐called
genotypes as necessitated by our family data requiring
rigorous Mendelian error checking, which is not straightforward with
dosage data (see also Walters et al for a similar approach to family
data18). Nonetheless, results for our top loci are similar when dosage
data were used for a confirmatory analysis (eg, rs10647170 1.53E‐
08). Another limitation inherent in both in silico functional analyses
and RNA expression analysis is the source of the data, which are largely
from subjects of European ancestry. As a result, conclusions from these
functional data may be limited when analyzing associated variants
identified in the COGA‐AA sample. Nonetheless, this represents an
important first step towards characterizing genetic risk in a key index
of AD liability. This study is also further strengthened by investigation
of both EA and AA individuals, who are known to differ in SRE scores.
We identified novel loci associated with SRE scores in both EA and
AA samples. As additional samples with SRE data, specifically SRE‐T,
become available, individual loci and polygenic risk scores from such
GWAS might explain even greater variance in LR. It will set the stage
for future interventions that might aim to interrupt progression to
AD.6,56 This boost in power necessitates further collection of SRE
data. Since the assessment is brief and easily administered, and is
included the PhenX tool kit (https://www.phenxtoolkit.org/), large
biobanks and nation‐wide data collection efforts are encouraged to
gather data on SRE to capture greater variability to susceptibility to
future problem drinking.ACKNOWLEDGEMENTS
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